Table 3 |
||||||||
|
Staining results of evaluable cores (%) |
||||||||
|
CALD |
CD9 |
CD99 |
FABP3 |
SERPINA1 |
TRPS1 |
VIM |
||
|
|
||||||||
|
Clear cell RCC |
No stain |
235/235 (100.0) |
215/229 (93.9) |
187/213 (87.8) |
137/232 (59.1) |
105/217 (48.4) |
208/212 (98.1) |
134/220 (60.9) |
|
Weak |
0/235 (0.0) |
10/229 (4.4) |
21/213 (9.9) |
53/232 (22.8) |
63/217 (29.0) |
2/212 (0.9) |
28/220 (12.7) |
|
|
Strong |
0/235 (0.0) |
4/229 (1.7) |
5/213 (2.3) |
42/232 (18.1) |
49/217 (22.6) |
2/212 (0.9) |
58/220 (26.4) |
|
|
|
||||||||
|
Chomophobe RCC |
No stain |
24/24 (100.0) |
0/24 (0.0) |
13/23 (56.5) |
13/24 (54.2) |
1/22 (4.5) |
6/22 (27.3) |
24/24 (100.0) |
|
Weak |
0/24 (0.0) |
2/24 (8.3) |
7/23 (30.4) |
5/24 (20.8) |
7/22 (31.8) |
11/22 (50.0) |
0/24 (0.0) |
|
|
Strong |
0/24 (0.0) |
22/24 (91.7) |
3/23 (13.0) |
6/24 (25.0) |
14/22 (63.6) |
5/22 (22.7) |
0/24 (0.0) |
|
|
|
||||||||
|
Papillary RCC |
No stain |
37/37 (100.0) |
36/36 (100.0) |
20/32 (62.5) |
17/36 (47.2) |
20/34 (58.8) |
31/31 (100.0) |
16/34 (47.1) |
|
Weak |
0/37 (0.0) |
0/36 (0.0) |
7/32 (21.9) |
9/36 (25.0) |
10/34 (29.4) |
0/31 (0.0) |
10/34 (29.4) |
|
|
Strong |
0/37 (0.0) |
0/36 (0.0) |
5/32 (15.6) |
10/36 (27.8) |
4/34 (11.8) |
0/31 (0.0) |
8/34 (23.5) |
|
|
|
||||||||
|
Unclassified RCC |
No stain |
13/13 (100.0) |
10/13 (76.9) |
4/9 (44.4) |
7/13 (53.8) |
6/11 (54.5) |
10/11 (90.9) |
4/12 (33.3) |
|
Weak |
0/13 (0.0) |
1/13 (7.7) |
3/9 (33.3) |
3/13 (23.1) |
4/11 (36.4) |
1/11 (9.1) |
2/12 (16.7) |
|
|
Strong |
0/13 (0.0) |
2/13 (15.4) |
2/9 (22.2) |
3/13 (23.1) |
1/11 (9.1) |
0/11 (0.0) |
6/12 (50.0) |
|
|
|
||||||||
|
Urothelial carcinoma |
No stain |
45/45 (100.0) |
46/46 (100.0) |
38/43 (88.4) |
29/46 (63.0) |
23/47 (48.9) |
38/44 (86.4) |
40/43 (93.0) |
|
Weak |
0/45 (0.0) |
0/46 (0.0) |
4/43 (9.3) |
12/46 (26.1) |
19/47 (40.4) |
5/44 (11.4) |
1/43 (2.3) |
|
|
Strong |
0/45 (0.0) |
0/46 (0.0) |
1/43 (2.3) |
5/46 (10.9) |
5/47 (10.6) |
1/44 (2.3) |
2/43 (4.7) |
|
|
|
||||||||
|
Oncocytoma |
No stain |
16/16 (100.0) |
7/16 (43.8) |
1/13 (7.7) |
3/16 (18.75) |
13/16 (81.3) |
9/15 (60.0) |
16/16 (100.0) |
|
Weak |
0/16 (0.0) |
6/16 (37.5) |
2/13 (15.4) |
6/16 (37.5) |
2/16 (12.5) |
4/15 (26.7) |
0/16 (0.0) |
|
|
Strong |
0/16 (0.0) |
3/16 (18.8) |
10/13 (76.9) |
7/16 (43.8) |
1/16 (6.3) |
2/15 (13.3) |
0/16 (0.0) |
|
|
|
||||||||
|
Angiomyolipoma |
No stain |
1/11 (9.1) |
10/10 (100.0) |
5/10 (50.0) |
7/10 (70.0) |
3/11 (27.3) |
7/12 (58.3) |
6/8 (75.0) |
|
Weak |
0/11 (0.0) |
0/10 (0.0) |
5/10 (50.0) |
3/10 (30.0) |
5/11 (45.5) |
5/12 (41.7) |
1/8 (12.5) |
|
|
Strong |
10/11 (90.9) |
0/10 (0.0) |
0/10 (0.0) |
0/10 (0.0) |
3/11 (27.3) |
0/12 (0.0) |
1/8 (12.5) |
|
|
|
||||||||
|
Williams et al. BMC Clinical Pathology 2009 9:9 doi:10.1186/1472-6890-9-9 |
||||||||